Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Psychoneuroendocrinology ; 38(9): 1803-13, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23571152

RESUMO

BACKGROUND: Cytokines and serotonin neurotransmission may play an important role on the development of psychopathological symptoms during interferon (IFN) treatment. The aim of the present study was to investigate the association between IFN-induced depression, anxiety and fatigue and functional genetic variants at the interleukin-6 gene (IL-6) and serotonin transporter gene (SERT). METHODS: 385 consecutive Caucasian outpatients with chronic hepatitis C initiating treatment with IFN-alpha and ribavirin were included. All patients were interviewed at baseline using the Structured Clinical Interview for DSM-IV (SCID-I) and those with a current major depressive disorder or anxiety disorder before starting treatment were excluded. Depression and anxiety were assessed at baseline during the treatment (at 4, 12, 24 and 48 weeks) using the Hospital Anxiety and Depression Scale and fatigue was evaluated using a visual analogue scale. The 5-HTTLPR region of SERT gene and the functional polymorphism located at the promoter region of IL-6 gene (rs1800795) were genotyped. RESULTS: Genotypic distribution was in the Hardy-Weinberg equilibrium for SERT (p=0.41) and for IL-6 (p=0.72) polymorphisms. At baseline we found only a significant effect of IL-6 polymorphism on fatigue symptoms. During antiviral treatment we reported that subjects with CC genotype (IL-6) presented significantly lower changes from baseline in IFN-induced depression (p=0.005) and IFN-induced anxiety (p=0.004). We did not find statistically significant differences on depression (p=0.21) or anxiety (p=0.15) between SS/SL and LL genotypes of SERT. CONCLUSIONS: Genetic variations in the IL-6 gene increase the risk of IFN-induced depression and anxiety. The IL-6 polymorphism was associated with fatigue rates in patients with chronic hepatitis C before treatment. Our study confirms the role of inflammatory mechanisms in IFN-induced psychopathological symptoms.


Assuntos
Antivirais/efeitos adversos , Ansiedade/induzido quimicamente , Depressão/induzido quimicamente , Fadiga/induzido quimicamente , Hepatite C Crônica/tratamento farmacológico , Mutação INDEL , Interferon-alfa/efeitos adversos , Interleucina-6/genética , Mutação Puntual , Polietilenoglicóis/efeitos adversos , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Serotonina/fisiologia , Adulto , Ansiolíticos/uso terapêutico , Antidepressivos/uso terapêutico , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Ansiedade/tratamento farmacológico , Ansiedade/genética , Estudos de Coortes , Depressão/tratamento farmacológico , Depressão/genética , Quimioterapia Combinada , Fadiga/genética , Predisposição Genética para Doença , Hepatite C Crônica/genética , Humanos , Interferon-alfa/administração & dosagem , Interferon-alfa/uso terapêutico , Interleucina-6/fisiologia , Pessoa de Meia-Idade , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/uso terapêutico , Regiões Promotoras Genéticas/genética , Estudos Prospectivos , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Ribavirina/administração & dosagem , Ribavirina/uso terapêutico , Proteínas da Membrana Plasmática de Transporte de Serotonina/fisiologia , População Branca
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA